The Human Stem Cells Institute announced unaudited consolidated revenue results for the first quarter of 2017 in accordance with the International Financial Reporting Standards (IFRS). The company's consolidated revenue amounted to RUB 115.007 million, a year-on-year increase of 22.8% - as a result of increase in revenue from all the company's products and services in the market.